ARWR – Arrowhead Pharmaceuticals, Inc.
ARWR — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.74
Margin Of Safety %
-21
Put/Call OI Ratio
0.48
EPS Next Q Diff
-1.59
EPS Last/This Y
-3.23
EPS This/Next Y
-1.06
Price
61.19
Target Price
81.4
Analyst Recom
1.5
Performance Q
-4.23
Upside
-67.3%
Beta
1.26
Ticker: ARWR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | ARWR | 60.68 | 0.34 | 0.93 | 39205 |
| 2026-03-10 | ARWR | 59.17 | 0.34 | 0.32 | 39589 |
| 2026-03-11 | ARWR | 57.86 | 0.34 | 0.42 | 40213 |
| 2026-03-12 | ARWR | 55.02 | 0.36 | 0.75 | 40606 |
| 2026-03-13 | ARWR | 55.01 | 0.36 | 0.73 | 40606 |
| 2026-03-17 | ARWR | 57.57 | 0.33 | 1.27 | 43326 |
| 2026-03-18 | ARWR | 56.71 | 0.33 | 1.26 | 43497 |
| 2026-03-19 | ARWR | 56.96 | 0.32 | 1.22 | 43161 |
| 2026-03-20 | ARWR | 56.32 | 0.30 | 0.37 | 42365 |
| 2026-03-23 | ARWR | 56.65 | 0.51 | 0.22 | 23805 |
| 2026-03-24 | ARWR | 56.25 | 0.51 | 0.11 | 24343 |
| 2026-03-25 | ARWR | 60.82 | 0.50 | 0.25 | 24677 |
| 2026-03-26 | ARWR | 60.79 | 0.47 | 0.31 | 27248 |
| 2026-03-27 | ARWR | 57.74 | 0.47 | 0.10 | 28294 |
| 2026-03-30 | ARWR | 57.61 | 0.48 | 0.28 | 28227 |
| 2026-03-31 | ARWR | 62.74 | 0.47 | 0.22 | 28403 |
| 2026-04-01 | ARWR | 62.87 | 0.46 | 0.74 | 29717 |
| 2026-04-02 | ARWR | 61.07 | 0.47 | 1.74 | 30585 |
| 2026-04-06 | ARWR | 61.12 | 0.48 | 0.25 | 30781 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | ARWR | 60.69 | -136.7 | -502.6 | -3.24 |
| 2026-03-10 | ARWR | 59.16 | -136.7 | -498.4 | -3.24 |
| 2026-03-11 | ARWR | 58.08 | -136.7 | -495.4 | -3.24 |
| 2026-03-12 | ARWR | 55.00 | -136.7 | -486.8 | -3.24 |
| 2026-03-13 | ARWR | 55.03 | -136.7 | -486.9 | -3.24 |
| 2026-03-17 | ARWR | 57.57 | -136.7 | -493.9 | -3.24 |
| 2026-03-18 | ARWR | 56.74 | -136.7 | -491.6 | -3.24 |
| 2026-03-19 | ARWR | 56.92 | -136.7 | -492.1 | -3.24 |
| 2026-03-20 | ARWR | 56.33 | -136.7 | -490.4 | -3.24 |
| 2026-03-23 | ARWR | 56.66 | -136.7 | -491.4 | -3.24 |
| 2026-03-24 | ARWR | 56.27 | -136.7 | -490.3 | -3.24 |
| 2026-03-25 | ARWR | 60.77 | -136.7 | -502.9 | -3.24 |
| 2026-03-26 | ARWR | 60.79 | -136.7 | -502.9 | -3.24 |
| 2026-03-27 | ARWR | 57.76 | -136.7 | -494.5 | -3.24 |
| 2026-03-30 | ARWR | 57.63 | -136.7 | -494.1 | -3.24 |
| 2026-03-31 | ARWR | 62.71 | -136.7 | -508.3 | -3.24 |
| 2026-04-01 | ARWR | 62.85 | -136.7 | -508.7 | -3.24 |
| 2026-04-02 | ARWR | 61.06 | -136.7 | -503.7 | -3.24 |
| 2026-04-06 | ARWR | 61.12 | -136.7 | -503.9 | -3.24 |
| 2026-04-07 | ARWR | 61.19 | -136.7 | -503.8 | -3.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | ARWR | -5.60 | 2.48 | 8.27 |
| 2026-03-10 | ARWR | -5.70 | 2.48 | 8.27 |
| 2026-03-11 | ARWR | -5.70 | 2.48 | 8.52 |
| 2026-03-12 | ARWR | -5.70 | 2.48 | 8.52 |
| 2026-03-13 | ARWR | -5.70 | 2.48 | 8.52 |
| 2026-03-17 | ARWR | -5.55 | 2.49 | 8.52 |
| 2026-03-18 | ARWR | -5.55 | 2.49 | 8.52 |
| 2026-03-19 | ARWR | -5.55 | 2.49 | 8.52 |
| 2026-03-20 | ARWR | -5.55 | 2.49 | 8.52 |
| 2026-03-23 | ARWR | -5.55 | 2.48 | 8.52 |
| 2026-03-24 | ARWR | -5.55 | 2.48 | 8.52 |
| 2026-03-25 | ARWR | -5.55 | 2.48 | 8.74 |
| 2026-03-26 | ARWR | -5.55 | 2.48 | 8.74 |
| 2026-03-27 | ARWR | -5.55 | 2.48 | 8.74 |
| 2026-03-30 | ARWR | -5.55 | 2.47 | 8.74 |
| 2026-03-31 | ARWR | -5.55 | 2.47 | 8.74 |
| 2026-04-01 | ARWR | -5.55 | 2.47 | 8.74 |
| 2026-04-02 | ARWR | -5.55 | 2.47 | 8.74 |
| 2026-04-06 | ARWR | -5.36 | 2.48 | 8.74 |
| 2026-04-07 | ARWR | -5.36 | 2.48 | 8.74 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.22
Avg. EPS Est. Current Quarter
-1.01
Avg. EPS Est. Next Quarter
-1.37
Insider Transactions
-5.36
Institutional Transactions
2.48
Beta
1.26
Average Sales Estimate Current Quarter
66
Average Sales Estimate Next Quarter
31
Fair Value
48.2
Quality Score
83
Growth Score
36
Sentiment Score
62
Actual DrawDown %
34.7
Max Drawdown 5-Year %
-88.9
Target Price
81.4
P/E
39.77
Forward P/E
PEG
P/S
7.85
P/B
14.79
P/Free Cash Flow
26.2
EPS
1.54
Average EPS Est. Cur. Y
-3.24
EPS Next Y. (Est.)
-4.3
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
18.54
Relative Volume
0.41
Return on Equity vs Sector %
8.1
Return on Equity vs Industry %
24.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-503.8
◆
ARWR
Healthcare
$61.18
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
52.6
Range 1M
64%
Sup Dist
1.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-32007.1%
EPS NY
-27.2%
52W%
76.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+0.5% upside
Upside
+0.5%
Quality
83
MoS
-21%
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 711
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
ARWR
Latest News
—
Caricamento notizie per ARWR…
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading